Project Grant R43AG063643

This federal Project Grant award of $1,183,821.00 from the National Institute on Aging (CFDA 93.866 Aging Research) is supporting research to investigate the relationship between auditory test performance and the development of Alzheimer's disease pathophysiology, including amyloid-beta plaques and tau tangles. The research, led by Dartmouth College, will expand on previous findings that central (rather than peripheral) auditory test results correlate better with markers of Alzheimer's disease...

GRANT SUMMARY Vasoptic Medical, Inc. received a $500,000 Phase I Project Grant awarded September 20, 2025, by the National Institute on Aging under the Aging Research program (CFDA 93.866) to develop VasoVue NV, a non-invasive imaging platform for early detection of Alzheimer's disease through assessment of neurovascular reactivity. The primary deliverable is proof-of-concept demonstration that retinal vascular response to flicker illumination stimulation can serve as a non-invasive biomarker...

This three-year, $658,002 National Science Foundation Engineering project grant funds research at Florida Atlantic University investigating changes in cerebral and retinal blood flow responses as a potential early diagnosis mechanism for Alzheimer's disease. The goal is to establish a viable, cost-effective early detection strategy through eye imaging procedures and new optical technologies measuring eye and brain blood flow changes associated with Alzheimer's. Machine learning tools will...

Federal Grant Award Summary The National Institute on Aging awarded Meganano Diagnostics Inc. a Project Grant of $483,346 under the Aging Research program (CFDA 93.866) to develop an RT-qPCR (reverse transcription quantitative polymerase chain reaction) assay for early diagnosis of Alzheimer's disease. The 12-month project, initiated September 15, 2025 and concluding August 31, 2026, focuses on translating preliminary findings demonstrating that T cell receptor (TCR) clonality changes in CD8+...

This Project Grant award from the National Institute on Aging (NIA), under the Aging Research federal grant program (CFDA 93.866), aims to investigate the presence of Alzheimer's disease (AD) biomarkers in nasally exhaled breath. The $440,000 award to Northwestern University will fund research to test the hypothesis that neural proteins associated with AD, such as tau and beta-amyloid, can be detected and quantified in nasally exhaled breath samples. The 2-year project period runs from...

Federal Grant Award Summary Oscilloscape, Inc. (operating as Oscillo Biosciences) received a $1,402,614 Project Grant award from the National Institute on Aging under the Aging Research program (CFDA 93.866), effective September 20, 2025, through September 19, 2026. The company is developing and testing SynchronyGamma (SYNG), an innovative wearable digital health device designed to deliver therapeutic intervention for aging adults with Alzheimer's Disease (AD) and Mild Cognitive Impairment...

Federal Grant Award Summary Tauvision, Inc. received a Project Grant of $986,768 from the National Institute on Aging under the Aging Research program (CFDA 93.866) awarded on September 20, 2025, with a completion date of September 19, 2026. The company is developing an innovative eyedrop-based diagnostic test for Alzheimer's Disease (AD) that utilizes a fluorescent dye to label pathological protein aggregates in the eye, which can be imaged using standard ophthalmology equipment. This...

This $427,625 Project Grant awarded by the National Institute on Aging (CFDA 93.866 Aging Research) to the University of Washington aims to develop and optimize two novel blood-based biomarker assays to improve clinical diagnosis and differential diagnosis of Parkinson's disease (PD) and multiple system atrophy (MSA). The key products and services to be delivered under this 2-year grant include: Further development and optimization of a flow cytometry-based assay (APOGEE) to directly quantify...

The National Institute on Aging (NIA) awarded a $454,024 Project Grant (CFDA 93.866 - Aging Research) to the Research Foundation For Mental Hygiene, Inc. (RFMH) to conduct research on high-frequency oscillations (HFOs) as a potential biomarker for Alzheimer's disease progression. The key goals of this 2-year project are to: (1) determine if HFOs originate in the hippocampus and expand to other brain regions as Alzheimer's pathology advances, (2) assess whether disrupting HFOs can improve...

This federal Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to develop a new blood-based biomarker for the early detection and monitoring of Alzheimer's disease (AD). The $431,826 award, made on September 15, 2024, will fund the development of monoclonal antibodies to detect a newly discovered, neurotoxic amyloid-beta (Aβ) peptide dimer that is specific to AD pathology in the brain. The project involves the University of Wollongong conducting...